David Hudesman, MD, on Managing IBD and Malignancy

In this video, Dr Hudesman, from NYU Langone Health, highlights the current literature on the management of inflammatory bowel disease with underlying malignancy, discusses if anti-tumor necrosis factor agents increase the risk of new or recurrent cancer in this patient population, and the importance of treating patients on a case-by-case basis.

 

David Hudesman, MD, is codirector of the Inflammatory Bowel Disease Center at NYU Langone Health and associate professor in the Department of Medicine at NYU Langone Health in New York, New York.

 

For more on IBD, visit the AIBD Newsroom.

 

Submit Feedback

Name